Menu

Generics

picture15

Commission urges Greece to make parallel trade fair

Generics/General | Posted 24/02/2012

The European Commission announced on 26 January 2012 that it wanted Greece ‘to establish fair play on parallel importation of medicinal products’.

picture14

Sun comes under fire from Pfizer

Generics/News | Posted 24/02/2012

Sun Pharmaceutical Industries (Sun Pharma) is coming under fire from Pfizer, as the generics major is sued for violating patents on Pfizer’s Protonix (pantoprazole).

picture13

WHO definitions of generics

Generics/General | Posted 24/02/2012

Confusion often surrounds terms used in the global field of generics and biosimilars.

picture05

Watson files ANDA for generic Beyaz

Generics/News | Posted 17/02/2012

Watson Pharmaceuticals (Watson) announced on 10 February 2012 that it had filed an Abbreviated New Drug Application (ANDA) with FDA for a generic version of Bayer HealthCare’s (Bayer) leading oral contraceptive Beyaz (drospirenone/ethinyl estradiol/levomefolate).

picture04

Italian physicians’ negative attitude to generics

Generics/General | Posted 17/02/2012

A row over generics prescribing has erupted in Italy, with the government and physicians at odds over changes to prescribing rules.

picture03

Sandoz submits ANDA for generic treprostinil

Generics/News | Posted 17/02/2012

US drugmaker United Therapeutics announced on 6 February 2012 that it had received a Paragraph IV Certification Notice Letter from Sandoz, the generics division of Swiss-based drug giant Novartis. The notice letter stated that Sandoz had submitted an Abbreviated New Drug Application (ANDA) to FDA requesting approval to market a generic version of the 10 mg/mL strength of Remodulin (treprostinil) injection.

picture 95

Tentative FDA approval for generic HIV treatment

Generics/News | Posted 10/02/2012

FDA announced on 31 January 2012 that it had given tentative approval for generic versions of GlaxoSmithKline’s (GSK’s) blockbuster AIDs treatment Epzicom (abacavir sulfate and lamivudine). The tentative approval enables India-based generics companies Cipla and Mylan to sell their generics to US aid programmes, but not yet in the US.

picture 93

Ranbaxy consent decree with FDA submitted to court

Generics/News | Posted 10/02/2012

Ranbaxy Laboratories (Ranbaxy) announced on 26 January 2012 that the consent decree with FDA that was signed on 20 December 2011 has been filed with the United States District Court for the District of Maryland.

picture 91

Generic and biosimilar user fee recommendations sent to Congress

Generics/News | Posted 03/02/2012

FDA has sent recommendations for user fee programmes, including those covering generic and biosimilar drugs, to US Congress. It is hoped that the fees will help speed up the delivery of safe and effective drugs to patients.

picture 88

Italy asked to comply with marketing rules for generics

Generics/News | Posted 03/02/2012

The news that the European Commission (EC) had finally issued a formal call on 26 January 2012 for Italy to comply with EU rules on the marketing authorisation of generic medicines was welcomed by the European Generic medicines Association (EGA) together with the Italian association for generic medicines (Assogenerici).

picture 85

Generics market to experience strong growth in 2010–2017

Generics/Research | Posted 03/02/2012

The global market for generic drugs will experience strong growth in the coming years due to patent expiries of blockbuster drugs worth US$150 billion between 2010 and 2017. Cost containment strategies being implemented by governments and healthcare service providers are also given credit for shifting sales towards cheaper generics.

picture 79

Watson expands in Asia with Ascent Pharmahealth

Generics/News | Posted 27/01/2012

US generics manufacturer Watson Pharmaceuticals announced on 24 January 2012 that it had acquired Ascent Pharmahealth, the Australia and Southeast Asia generics subsidiary of Strides Arcolab, in a deal worth Australian dollars (A$) 375 million.

picture 74

Factors important for generics substitution in Finland

Generics/Research | Posted 20/01/2012

What factors do patients take into account when deciding to accept or reject generics substitution? This is the question asked in a recent research article [1].

picture 71

Teva outlines expansion plans in Asia

Generics/News | Posted 20/01/2012

Generics giant Teva is looking for deals in Asia, which the company believes will see strong future expansion in the use of generics.

picture 69

Generic nasal spray approved by FDA

Generics/News | Posted 20/01/2012

India-based generics manufacturer Wockhardt announced on 10 January 2012 that it had received final approval from FDA for marketing a generic version of GlaxoSmithKline’s nasal spray allergy treatment Flonase (fluticasone).

picture45

Teva gains tentative approval for generic atorvastatin

Generics/News | Posted 13/01/2012

Teva announced on 1 December 2011 that it had received tentative approval from FDA for its generic version of Pfizer’s blockbuster cholesterol-reducing medication Lipitor (atorvastatin).

picture57

Pfizer continues to fight for Lipitor

Generics/News | Posted 16/12/2011

With the patent expiry of Pfizer’s blockbuster cholesterol-reducing drug Lipitor (atorvastatin) on 30 November 2011, Pfizer it seems is pulling out all the stops to delay generic erosion of its market share.

picture56

Ranbaxy may settle with FDA for generic atorvastatin launch

Generics/News | Posted 16/12/2011

According to The Times of India, generics giant Ranbaxy Laboratories and FDA are getting closer to reaching an agreement to solve the Indian drugmaker’s regulatory troubles.